The collaboration aims to develop a new value chain for low-carbon, bio-based acrylic resins by leveraging breakthrough proprietary technology.  (Source: © Dee karen - stock.adobe.com)
Sustainability

Arkema, Catalyxx to Develop New Value Chain for Low-Carbon, Bio-Based Acrylic Resins

The partnership between Arkema and Catalyxx aims to accelerate the production of low-carbon, bio-based acrylic resins by making use of proprietary technology. Catalyxx intends to develop an innovative industrial facility to produce bio-alcohols while Arkema is assessing the use of these bio-alcohols as feedstocks for the commercial-scale production of bio-based acrylic resins with lower carbon footprint.

Read on

Galleries

During a tour with live demonstrations, Bausch+Ströbel showcases GMP-compliant solutions in filling technology. (Source: Bausch+Ströbel)
PharmaXchange at Bausch+Ströbel

Is Annex 1 the Elephant in the Room?

A metaphor for an obvious, unresolved problem that everyone notices but no one talks about – that’s the famous elephant in the room. In the pharmaceutical industry, one specific topic immediately comes to mind: Annex 1. However, PharmaXchange at Bausch+Ströbel impressively demonstrated that this supposed “elephant” was not ignored here, but rather tamed – and viewed as an opportunity.

Read on